Airway Management in Dentistry: Advanced Diagnostic and Treatment Protocols

Advanced Diagnostic and Treatment Protocols

General Dentistry · Seminar week 18 · released July 27, 2026 · includes a discussion video

Airway management has become a vital aspect of modern dentistry, with implications for sleep apnea treatment and pediatric airway development. Dr. Jeff Rouse's insights into…

Learning Objectives

Differentiate systemic-risk–dominant and functional-symptom–dominant airway presentations while maintaining an appropriate differential diagnosis.
Perform a structured dental airway screen without exceeding the dentist’s diagnostic scope.
Select appropriate candidates for custom, titratable mandibular advancement therapy.
Apply a safe, objective titration and follow-up protocol for oral appliance treatment.
Critically appraise the Seattle Protocol as a provisional appliance-selection heuristic rather than a validated diagnostic standard.
Evaluate pediatric sleep-disordered breathing using developmentally appropriate referral and treatment pathways.
Coordinate longitudinal airway care among dentistry, sleep medicine, otolaryngology, orthodontics, surgery, pediatrics, and cardiometabolic specialists.

Overview of Airway Dentistry and Its Importance in Clinical Practice

%%FIG0%% Airway dentistry is best understood as the dental contribution to recognizing and managing sleep-related breathing disorders, craniofacial risk factors, oral consequences of abnormal breathing, and peri-procedural airway risk. It is broader than fabricating an appliance for obstructive sleep apnea (OSA), but it is not an independent medical specialty and does not confer authority to diagnose every patient with fatigue, bruxism, or a narrow palate as having an airway disorder. The dentist’s highest-value roles are repeated screening, detailed examination of the oral–craniofacial complex, safe delivery of prescribed oral appliance therapy, recognition of treatment complications, and closed-loop referral.

Jeff Rouse’s airway-prosthodontic model emphasizes creating the least physiologically stressful environment for breathing rather than concentrating exclusively on the apnea–hypopnea index (AHI). That framing is useful when it prompts clinicians to examine nasal patency, tongue space, mandibular position, vertical dimension, dentition, and sleep symptoms together. It becomes unsafe when “anatomical optimization” is assumed to cure a heterogeneous sleep disorder. Adult OSA reflects an interaction among pharyngeal collapsibility, impaired upper-airway muscle compensation, ventilatory instability or high loop gain, and the arousal threshold—not anatomy alone (PMID: 33064953).

During sleep, reduced neuromuscular tone allows a vulnerable pharynx to narrow under inspiratory negative pressure. Repetitive obstruction produces intermittent hypoxemia, carbon-dioxide fluctuation, arousals, sympathetic surges, and large intrathoracic pressure swings. The downstream phenotype may include sleepiness, impaired vigilance, resistant hypertension, atrial fibrillation, metabolic dysfunction, and increased crash risk. Association does not guarantee that correcting AHI will reverse every comorbidity: in the SAVE trial, CPAP improved snoring, sleepiness, mood, and quality of life but did not reduce the composite cardiovascular endpoint in a largely nonsleepy secondary-prevention population with modest nightly use (PMID: 27571048). Treatment goals should therefore include symptoms, oxygenation, respiratory-event control, adherence, blood pressure, safety, and patient priorities—not an isolated number.

Dentists repeatedly encounter risk markers such as retrognathia, a high or narrow palate, large tongue, tonsillar enlargement, severe overjet, obesity, tooth wear, dry mouth, morning headache, and reports of snoring or witnessed apnea. None is diagnostic. STOP-Bang, the Epworth Sleepiness Scale, and pediatric symptom inventories stratify risk but cannot replace polysomnography or an appropriately selected home sleep apnea test. The AASM requires diagnostic testing to follow a comprehensive sleep evaluation; a negative or technically inadequate home study should be followed by polysomnography when suspicion remains high (PMID: 28162150).

Framework: Think in three layers: identify risk, establish a medical diagnosis, and then match treatment to mechanism and patient preference. Dentistry leads the first layer, contributes substantially to the third, and collaborates with the medical clinician responsible for the second.

MUST ACT: Ask every high-risk patient about habitual snoring, witnessed pauses, choking or gasping, nonrestorative sleep, nocturia, morning headache, daytime sleepiness, drowsy driving, prior sleep testing, and current PAP or appliance use. Urgent medical referral is warranted for severe sleepiness with driving risk, prolonged witnessed apneas, major nocturnal hypoxemia, uncontrolled cardiovascular disease, or suspected hypoventilation.

Airway information also changes routine dental planning. Periodontal stability, tooth prognosis, implant position, restorative contours, occlusion, temporomandibular-joint function, and anticipated appliance retention should be considered before extensive rehabilitation. Patients with known or suspected OSA merit particular care before moderate or deep sedation because sedatives, anesthetics, opioids, supine positioning, and residual neuromuscular depression can compound obstruction. Document OSA severity, therapy adherence, prior anesthetic difficulty, and the plan for ventilation monitoring and rescue.

Teaching Point: The dental airway examination is a high-sensitivity case-finding opportunity, not a stand-alone sleep study.

Audience Poll: Which finding most often prompts an airway conversation in your practice: witnessed apnea, hypertension, tooth wear, craniofacial anatomy, or unexplained fatigue?

Classifying Airway Patient Types: Systemic vs. Functional Symptoms

%%FIG1%% The “systemic versus functional” distinction is a useful clinical entry point, but it is not a validated diagnostic classification. Patients commonly cross categories, and neither age nor body habitus reliably excludes important disease. The classification should organize questions and referrals—not determine treatment before objective testing.

The systemic-risk–dominant patient resembles the traditional OSA presentation: middle-aged or older, often but not always male, with central adiposity, a large neck circumference, loud snoring, witnessed pauses, hypertension, atrial fibrillation, type 2 diabetes, prior stroke, or heart failure. Sleepiness may be prominent, but many high-risk patients deny it because symptoms developed gradually or because they avoid sedentary situations. Women may present with fatigue, insomnia, morning headache, or mood symptoms rather than classic witnessed apnea. A normal Epworth score therefore cannot exclude clinically consequential OSA.

MUST ACT: In a patient with resistant hypertension, atrial fibrillation, recurrent stroke, pulmonary hypertension, severe obesity, or unexplained nocturnal hypoxemia, do not let the absence of sleepiness terminate the evaluation.

The functional-symptom–dominant patient is often younger, leaner, and referred because of nonrestorative sleep, insomnia, headaches, concentration problems, bruxism, jaw discomfort, dry mouth, reflux symptoms, chronic nasal obstruction, or restless sleep. Examination may show retrognathia, a narrow arch, high palate, tongue scalloping, crossbite, or habitual open-mouth posture. Some patients have flow limitation and respiratory-effort–related arousals despite a low AHI. An attended polysomnogram can identify arousals and calculate a respiratory disturbance index; a home study may underestimate disease because it lacks electroencephalographic sleep time and generally cannot score respiratory-effort–related arousals.

These symptoms remain nonspecific. Insufficient sleep, circadian delay, chronic insomnia, restless legs syndrome, iron deficiency, anemia, hypothyroidism, depression, anxiety, medication effects, alcohol, cannabis, chronic pain, allergic rhinitis, asthma, gastroesophageal reflux, primary temporomandibular disorder, and independent bruxism can produce overlapping complaints. Opioid exposure, neuromuscular disease, advanced cardiopulmonary disease, stroke, and obesity hypoventilation raise concern for central events or hypoventilation rather than purely obstructive disease. Such patients generally require attended polysomnography rather than a routine home test.

Framework: Overlay the symptom classification with four mechanistic questions: How collapsible is the airway? How effectively do dilator muscles respond? Is ventilatory control unstable? At what level of respiratory stress does the patient arouse? A mandibular device primarily addresses collapsibility; it does not correct central apnea, opioid-related hypoventilation, or every high-loop-gain phenotype.

Interpret sleep-study labels carefully. In adults, AHI values of 5–14.9, 15–29.9, and at least 30 events per hour conventionally define mild, moderate, and severe OSA. These bins do not capture event duration, REM or positional concentration, hypoxic burden, arousal intensity, or susceptibility to consequences. A patient with an AHI of 12 and marked desaturation may deserve more urgency than one with an AHI of 18, minimal oxygen disturbance, and no symptoms. Home studies report a respiratory-event index using monitoring time, which may dilute the apparent severity in a patient awake for much of the recording.

The dental examination should document nasal complaints; tonsil and tongue size; Mallampati or Friedman tongue position; mandibular projection; overjet; arch form; palatal depth; periodontal and tooth status; protrusive range; TMJ and muscle findings; and signs of xerostomia or wear. Static CBCT airway volume can assist selected dental or surgical planning but cannot reproduce sleep-state muscle tone or establish OSA. Similarly, transient improvement when the patient protrudes the jaw while awake does not predict adequate nocturnal control.

Decision Point: A lean 29-year-old with fatigue, bruxism, insomnia, and a narrow palate has a functional-symptom–dominant presentation. The next step is not expansion or an empiric MAD; it is a sleep and medical differential, treatment of obvious nasal disease, and objective testing if suspicion remains.

Nuance: Tooth wear and sleep bruxism may coexist with sleep-disordered breathing, but they are neither sufficiently sensitive nor specific to serve as airway biomarkers.

Audience Poll: Which alternative diagnosis is most often missed when a younger patient’s fatigue is attributed to airway anatomy?

Mandibular Advancement Devices: Indications and Limitations

%%FIG2%% A mandibular advancement device (MAD), also called a mandibular advancement splint, advances and stabilizes the mandible while worn. This moves the tongue and connected soft tissues anteriorly, tensions the palatoglossal and lateral pharyngeal tissues, and can reduce upper-airway collapsibility. The effect is nightly and mechanical; routine adult MAD therapy does not permanently enlarge the skeleton or remove the underlying predisposition to OSA.

The joint AASM/AADSM guideline supports oral appliance therapy for adults with OSA who cannot tolerate CPAP or prefer an alternative, and recommends a custom, titratable device delivered by a qualified dentist rather than a noncustom “boil-and-bite” appliance. It also requires dental oversight, objective follow-up sleep testing, and periodic review by both dental and medical clinicians (PMID: 26094920). Primary snoring should not be treated until OSA has been excluded by the responsible medical provider.

Good candidates have sufficient stable dentition or another reliable retention strategy, controlled caries and periodontal disease, an acceptable protrusive range, and manageable TMJ and muscle status. Active tooth mobility, untreated dental disease, inadequate retention, severely restricted mandibular movement, or painful function-limiting TMD requires correction or specialist planning. Severe OSA is not an absolute contraindication when CPAP is refused or intolerable, but the consequences of incomplete response are greater and objective verification is mandatory.

MUST ACT: Do not infer efficacy from reduced snoring, a wearable, or subjective energy alone. The final appliance position must be tested with physician-interpreted polysomnography or an appropriately ordered home sleep apnea test.

There is no universal millimeter “dose.” A practical protocol records the full comfortable retrusive-to-protrusive range and often begins near 25%–50% of available advancement with minimal necessary vertical opening. After one to four weeks of acclimatization, the device may be advanced in approximately 0.25–1 mm increments every one to two weeks, provided symptoms persist and the teeth, muscles, and joints remain comfortable. Stop when the agreed objective target is reached, additional advancement produces no benefit, or adverse effects exceed benefit. More protrusion is not automatically better, and excessive vertical opening can worsen airway mechanics in some patients.

The 2025 CHOICE multicentre randomized crossover trial illustrates efficacy versus effectiveness. MAD adherence averaged 6.0 hours per night compared with 5.3 hours for CPAP, but CPAP achieved substantially greater physiologic event suppression. Patient-centred outcomes improved with both therapies, and 55% of patients completing the observational phase chose to alternate them (PMID: 39638418). The lesson is not that MADs outperform CPAP; it is that access to two acceptable treatments may increase total treated sleep time.

CRESCENT randomized 220 adults with hypertension, elevated cardiovascular risk, and moderate-to-severe OSA. At six months, MAD was noninferior to CPAP for reduction in 24-hour mean arterial pressure, with higher rates of use for at least six hours per night, although CPAP controlled residual respiratory events much more completely (PMID: 38588926). In the severe-OSA substudy, median AHI fell from 44.0 to 20.9 with MAD and from 50.7 to 2.1 with CPAP; MAD use was higher, and both improved quality of life (PMID: 40888163). These results support a monitored alternative, not acceptance of untreated residual severe disease or claims of proven prevention of myocardial infarction or stroke.

Short-term adverse effects include salivation, dry mouth, tooth tenderness, mucosal irritation, morning bite change, muscle soreness, and TMJ symptoms. Long-term treatment commonly reduces overjet and overbite through upper-incisor retroclination, lower-incisor proclination, and mesial mandibular dental movement. Baseline digital models or casts, photographs, periodontal charting, and occlusal records make change measurable. Morning mandibular exercises or a repositioning guide may help recovery, but they do not replace surveillance.

Decision Point: If a patient remains sleepy or hypertensive despite excellent device use, first verify residual AHI, oxygenation, sleep duration, and adherence rather than advancing indefinitely. Consider further titration, positional therapy, PAP–MAD combination therapy, weight management, ENT evaluation, or surgery according to the residual mechanism.

Audience Poll: Which outcome should limit further advancement first: residual snoring, mild transient pressure, persistent TMJ pain, progressive occlusal change, or a normalized objective study?

The Seattle Protocol: A Phased Approach to Airway Management

%%FIG3%% The Seattle Protocol, attributed to Jeffrey Rouse and Greggory Kinzer, is a creator-developed airway-prosthodontic sequence that uses reversible provisional interventions to explore how nasal breathing, vertical dimension, and mandibular advancement affect symptoms. Rouse described an “autonomic nervous system trial” and an interdisciplinary resolution algorithm in a narrative review, not a prospective outcomes trial (PMID: 27213777). The protocol is therefore best presented as a chairside appliance-selection and hypothesis-generating heuristic—not as a validated diagnostic test, OSA treatment guideline, or substitute for medical sleep evaluation.

Before the numbered sequence, establish a baseline. Document the sleep diagnosis, study date, AHI or respiratory-event index, oxygen nadir, positional and REM dependence, symptoms, blood pressure, nasal complaints, medications, alcohol use, dentition, periodontal stability, TMJ status, and occlusion. If OSA is only suspected, refer for medical evaluation before treating “primary snoring” or relying on a temporary splint. Define in advance what constitutes improvement and how it will be objectively verified.

Framework: The six creator-described steps progressively alter three variables:

Nasal-breathing trial: Traditionally, the patient undertakes approximately two weeks of nasal-breathing instruction, sometimes with a nasal dilator and mouth tape. Nasal obstruction must first be evaluated and treated; mouth closure is not a benign default intervention.
Lower flat-plane provisional splint: A temporary mandibular appliance increases oral vertical dimension without intentional advancement. Evaluate comfort, jaw function, sleep symptoms, and any worsening of snoring or breathing.
Conservative advancement: The lower appliance is modified to position the mandible approximately 3 mm anteriorly, adding horizontal advancement to the vertical change.
Separate upper and lower splints: Protrusive stops are removed and an upper component is added, increasing vertical dimension while leaving the mandible freer to move.
Combined vertical opening and advancement: The appliances are linked or configured to add approximately 3 mm of protrusion while retaining the altered vertical dimension.
Progressive titration: Mandibular advancement is increased incrementally to identify the best balance among symptoms, respiratory control, comfort, and jaw tolerance.

Nuance: The exact appliances and sequence vary among descriptions. That variability, together with the absence of independent prospective validation, prevents the protocol from being treated as a standardized diagnostic instrument.

The mouth-taping component deserves particular caution. A 2025 systematic review found only ten small, generally poor-quality studies, inconsistent benefits, and potential harm when nasal obstruction is present (PMID: 40397877). Experimental mouth closure has also worsened airflow in some patients with high baseline oral breathing and velopharyngeal obstruction (PMID: 39361293). Do not tape the mouth of a patient with untreated nasal obstruction, vomiting or aspiration risk, impaired ability to remove the tape, sedative use, or unassessed sleep-disordered breathing. Nasal saline, allergy management, external dilators, humidification, or ENT referral may be safer first steps.

Teaching Point: A response to a provisional splint may support a treatment hypothesis, but it does not prove that airway obstruction caused the patient’s bruxism, headache, reflux, or fatigue. Placebo effects, altered sleep position, regression to the mean, and concurrent behavioral changes remain possible.

Use the protocol’s reversibility to avoid premature definitive dentistry. If a conservative provisional position is comfortable and objectively effective, it can inform a custom titratable device or restorative design. If adequate control requires extreme advancement, excessive opening, or an intolerable jaw position, do not reproduce that position permanently. The finding should instead prompt reconsideration of PAP, combination therapy, weight management, nasal or pharyngeal surgery, orthodontic treatment for a genuine dentofacial indication, or maxillomandibular advancement in a carefully selected patient.

MUST ACT: Temporary appliances are short-term trials. They require supervision for tooth movement, soft-tissue injury, periodontal loading, TMJ symptoms, device fracture, and incomplete OSA control.

Decision Point: A patient who “feels better” at step three but retains an AHI of 22 events per hour has demonstrated subjective benefit, not therapeutic success. Escalate or combine treatment rather than declaring the airway corrected.

Audience Poll: Would a subjective response during a provisional phase change your treatment plan if oxygenation and respiratory-event frequency were unchanged?

Pediatric Considerations: Early Interventions and Developmental Impacts

%%FIG4%% Pediatric sleep-disordered breathing is not simply adult OSA in a smaller airway. Adenotonsillar hypertrophy, nasal inflammation, obesity, craniofacial development, neuromuscular tone, and syndromic disease interact across growth. Children may present with habitual snoring, labored breathing, witnessed pauses, restless sleep, unusual neck extension, enuresis, morning headache, difficult awakening, growth concerns, sleepiness, irritability, hyperactivity, or inattention. Dental findings—including a high narrow palate, posterior crossbite, retrognathia, open-mouth posture, enlarged tonsils, or tongue crowding—are risk markers, not proof of OSA.

MUST ACT: Ask whether a child snores at least three nights per week and whether caregivers observe pauses, gasping, labored breathing, restless sleep, or daytime behavioral change. Snoring plus symptoms warrants referral to pediatrics, pediatric sleep medicine, or ENT rather than diagnosis from CBCT, photographs, or dental examination alone.

Polysomnography remains the reference standard. Common pediatric obstructive AHI bands are 1–4.9 events per hour for mild, 5–9.9 for moderate, and at least 10 for severe disease, although symptoms, gas exchange, comorbidity, age, and sleep architecture also influence urgency. Routine home sleep apnea testing is not recommended for diagnosing children because available devices may miss arousals, hypoventilation, and pediatric event patterns. The AAP guideline recommends screening children for snoring, obtaining polysomnography when snoring is accompanied by OSA findings, and using adenotonsillectomy as first-line therapy when adenotonsillar hypertrophy is present (PMID: 22926173).

The Childhood Adenotonsillectomy Trial randomized 464 children aged five to nine. Early surgery did not significantly improve the primary objective attention or executive-function outcome at seven months, but it improved symptoms, caregiver-rated behavior, quality of life, and polysomnographic findings; PSG normalized in 79% after surgery versus 46% with watchful waiting (PMID: 23692173). In the PATS trial of 459 children with snoring and an obstructive AHI below 3, adenotonsillectomy again did not improve the two primary executive-function and attention endpoints, although behavior, symptoms, sleepiness, quality of life, blood-pressure percentiles, and progression of sleep-disordered breathing favored surgery (PMID: 38051326). These findings support shared decisions—not claims that surgery cures ADHD.

Persistent disease is common, especially with obesity, severe baseline OSA, Down syndrome, craniofacial differences, or neuromuscular disorders. Management may include CPAP, weight intervention, treatment of nasal inflammation, or site-specific surgery. Current ATS guidance conditionally permits adding montelukast for up to approximately 12 weeks in selected children already receiving an intranasal steroid, with close monitoring for mood or behavioral effects because of the FDA boxed warning; evidence certainty is very low (PMID: 37890009). These medications belong under pediatric or ENT supervision, not routine dental prescribing.

Nuance: Rapid maxillary expansion can correct a true transverse maxillary deficiency and may improve nasal dimensions, but anatomical change does not guarantee sleep-state physiologic control. A 2023 umbrella review found no consistent long-term evidence supporting RME as a general pediatric OSA treatment (PMID: 36894478); a 2026 controlled-evidence update likewise urged extreme caution because spontaneous improvement and weak control groups limit inference (PMID: 42074778). Consider expansion only when a trained orthodontist identifies a genuine transverse deficiency—often a high narrow palate with posterior crossbite—and when the sleep team agrees it addresses part of the residual phenotype. Do not expand a normally proportioned arch prophylactically to “prevent adult apnea.”

Teaching Point: Sleep-disordered breathing can contribute to or mimic hyperactivity and inattention, while ADHD or a learning disorder can exist independently. Evaluate both pathways and never discontinue neurodevelopmental treatment solely because an airway intervention is planned.

Peri-procedural safety is a separate pediatric airway domain. The ESAIC–BJA–focused review identified by PMID 39556153 concerns acute anesthetic airway assessment, oxygenation, intubation, extubation, equipment, and human factors; it does not validate orthodontic expansion or pediatric OSA treatment. Children with significant OSA may be unusually sensitive to sedatives and opioids and may need hospital-based anesthesia, enhanced monitoring, or postoperative observation.

Decision Point: A seven-year-old with nightly snoring, enuresis, hyperactivity, 3+ tonsils, and a posterior crossbite should receive parallel ENT/sleep and orthodontic assessments. Establish and treat the sleep phenotype first; consider expansion only for the documented skeletal indication and reassess OSA afterward.

Audience Poll: When a child has both tonsillar hypertrophy and maxillary constriction, which discipline should coordinate the sequence and objective reassessment?

Integrating Airway Management with Multidisciplinary Teams

%%FIG5%% Successful airway management requires explicit ownership of diagnosis, treatment delivery, and outcome verification. Informal referrals fail when the dentist assumes the physician will monitor the appliance, the physician assumes the dentist repeated a sleep study, and neither clinician tracks residual disease or progressive occlusal change.

Framework: Use a closed-loop pathway: dental case finding, medical diagnosis, shared treatment selection, dental implementation when indicated, objective efficacy testing, and lifelong surveillance.

The general dentist identifies risk, documents oral and craniofacial findings, stabilizes dental disease, and refers. The sleep physician or other legally authorized medical provider evaluates the differential, determines whether polysomnography or home testing is appropriate, diagnoses OSA or an alternative disorder, and establishes treatment goals. Screening questionnaires, pulse oximetry, wearables, and automatically scored home data should not independently determine diagnosis or treatment.

For PAP therapy, the sleep team, respiratory therapist, and equipment provider should address mask fit, pressure intolerance, leak, humidification, nasal symptoms, aerophagia, and behavioral barriers before labeling the patient “CPAP intolerant.” For oral appliance therapy, the qualified dentist evaluates teeth, restorations, periodontal support, protrusive range, TMJ function, dexterity, nasal symptoms, and retention; records the baseline bite; delivers a custom titratable device; and manages oral adverse effects. The medical provider verifies efficacy after titration. Review every six months during the first year and at least annually thereafter, with earlier reassessment after weight change, symptom recurrence, new cardiovascular disease, device replacement, or major dental work.

MUST ACT: Every referral should contain the question being asked, the relevant study and treatment data, and a request for the result to return. “Evaluate airway” is not an adequate handoff.

ENT evaluates persistent nasal obstruction, septal or turbinate disease, tonsils and adenoids, lingual tonsils, laryngeal abnormalities, and site-specific surgery. Orthodontists determine whether a true transverse or sagittal dentofacial discrepancy merits growth modification or expansion. Oral and maxillofacial surgeons assess skeletal procedures such as maxillomandibular advancement. Drug-induced sleep endoscopy may help selected surgical or neurostimulation planning but does not replace standard sleep testing. Orofacial myofunctional therapy can support nasal breathing, lip seal, tongue function, and adherence in selected patients; its role is adjunctive rather than a replacement for effective treatment of moderate or severe OSA.

Primary care, cardiology, endocrinology, and obesity medicine manage hypertension, atrial fibrillation, diabetes, alcohol and sedative exposure, and weight. SURMOUNT-OSA established that tirzepatide reduced AHI, hypoxic burden, body weight, and systolic blood pressure in adults with obesity and moderate-to-severe OSA (PMID: 38912654). In the United States, tirzepatide is approved for this population with diet and activity. Medical dosing starts at 2.5 mg subcutaneously weekly for four weeks, increases to 5 mg, and may increase by 2.5 mg after at least four weeks at each level toward an OSA maintenance dose of 10 or 15 mg weekly. It does not provide immediate pneumatic splinting, and repeat sleep assessment is necessary as weight and treatment requirements change. Because tirzepatide delays gastric emptying, dental anesthesia teams must identify its use and follow current medication, fasting, aspiration-risk, and anesthetic guidance.

Teaching Point: Combination therapy is often more rational than serial failure. Examples include MAD plus positional therapy for residual supine OSA, MAD plus PAP to reduce required pressure, weight treatment plus PAP, or nasal surgery to improve PAP tolerance.

Shared outcomes should extend beyond AHI. Track oxygen nadir and burden when available, sleepiness, driving safety, insomnia, quality of life, blood pressure, adherence, adverse effects, and patient-defined function. A technically successful device that is not worn is ineffective; a comfortable device leaving severe hypoxemia is inadequate.

Decision Point: Escalate when objective disease remains clinically important despite tolerated therapy. Options include further titration, PAP optimization, combination therapy, weight-directed treatment, hypoglossal nerve stimulation in eligible adults, upper-airway surgery, or maxillomandibular advancement. The choice depends on anatomy, physiology, comorbidity, severity, preference, and local expertise.

Audience Poll: In your current referral network, who owns the step of confirming efficacy after an oral appliance reaches its therapeutic position?

Case of the Middle-Aged Patient with OSA and Hypertension

A 50-year-old man with BMI 31 kg/m², treated hypertension, loud snoring, witnessed pauses, morning headache, and an Epworth Sleepiness Scale score of 13 is referred after abandoning CPAP. Physician-interpreted polysomnography showed an AHI of 24 events per hour, increasing to 42 supine, an oxygen nadir of 83%, and no meaningful central apnea. He stopped CPAP because of nasal congestion, mask leak, and aerophagia. He denies jaw pain but reports occasional drowsiness during his afternoon commute.

MUST ACT: Address immediate safety first. He should avoid driving when sleepy and receive expedited sleep-clinic follow-up. Appliance fabrication is not an adequate response to active drowsy-driving risk without interim planning.

The first task is to determine whether CPAP intolerance is remediable. The sleep team reviews pressure data and leak, offers a different interface, adjusts humidification, and refers persistent nasal obstruction for allergy or ENT assessment. Alcohol near bedtime and sedating medications are reviewed. The patient understands that CPAP remains the most predictably efficacious option but continues to decline it after a supported retrial.

Dental examination shows 26 teeth, stable periodontal support, no active caries, intact posterior retention, 9 mm of comfortable protrusive range, normal opening, and no TMJ or muscle tenderness. Baseline scans, photographs, overjet, overbite, periodontal findings, and protrusive range are recorded. Mild mandibular retrusion may favor a mechanical response, but it is not presented as a guarantee. The physician and dentist agree on a custom titratable MAD, with the objectives of improving symptoms and oxygenation, reducing AHI substantially, and treating as much of the habitual sleep period as possible.

The construction bite begins at approximately 4 mm—less than half of his measured protrusive range—with limited vertical opening. After two weeks of adaptation, advancement proceeds by 0.5 mm approximately weekly while monitoring tooth tenderness, morning bite recovery, muscle pain, TMJ symptoms, snoring, and sleepiness. Advancement pauses at 6 mm because symptoms have improved and further movement causes transient incisor tenderness. A morning repositioning guide and mandibular range-of-motion exercises are provided.

After eight weeks at the stable position, a physician-ordered home sleep apnea test shows a respiratory-event index of 7 events per hour, oxygen nadir of 90%, and residual events concentrated supine. The result is a meaningful response but not permission to discontinue surveillance. Because further advancement is poorly tolerated, the team adds positional therapy rather than forcing the mandible forward. If sleepiness or hypoxemia persisted, attended polysomnography, PAP–MAD combination therapy, or another treatment pathway would be preferred.

Teaching Point: This is treatment of a chronic disorder, not delivery of a dental product. The clinically important sequence is diagnosis, informed selection, careful titration, objective verification, management of residual disease, and long-term review.

His primary-care clinician continues antihypertensive therapy and home blood-pressure monitoring. CRESCENT supports MAD as a reasonable alternative for blood-pressure reduction in a similar high-risk phenotype, but it does not justify reducing antihypertensive medication without measured blood-pressure response or imply protection from hard cardiovascular events (PMID: 38588926). Weight-management options are discussed independently of device therapy.

At three and six months, the dentist reassesses adherence, device integrity, periodontal health, TMJ function, overjet, overbite, and morning occlusion. Thereafter, dental and sleep reviews occur at least annually. Repeat objective testing is arranged if weight changes substantially, snoring or sleepiness returns, hypertension worsens, atrial fibrillation develops, major restorative work changes device fit, or a replacement appliance is fabricated.

Decision Point: If the follow-up study had shown an AHI of 21 despite nightly use, symptom improvement alone would not justify continuation as monotherapy. The team would revisit PAP, combination therapy, positional dependence, weight treatment, ENT assessment, and surgical options.

Audience Poll: At what point in this case would you document CPAP as genuinely intolerable rather than insufficiently optimized?

Tonight on Shift

Screen for snoring, witnessed obstruction, sleepiness, drowsy driving, hypertension, and prior sleep testing; refer red flags urgently.
Treat oral and craniofacial findings as risk markers, never as stand-alone proof of OSA or its mechanism.
Use only a custom, titratable MAD in an appropriate adult after medical diagnosis, then verify the final position objectively.
Apply the Seattle Protocol only as a supervised provisional heuristic; do not use mouth taping or symptom response as diagnostic evidence.
Refer symptomatic children for pediatric sleep or ENT evaluation before expansion, and reserve orthodontic treatment for a documented dentofacial indication.
Close the loop among dentistry, sleep medicine, ENT, orthodontics, surgery, and cardiometabolic care with named owners for efficacy testing and follow-up.

Read this seminar as Markdown · All seminars · Lecture library · Question bank